Meridian Bioscience Inc. has officially launched its Analyte Specific Reagent (ASR) line of products.
The first ASR products to hit the market will be a primer set and probes for the detection of Helicobacter pylori as well as the targeting sequence associated with H. pylori strains, which are resistant to Clarithromycin.
“As a consistent innovator and market share leader for in vitro diagnostic devices, it is important that Meridian’s diagnostic tools for emerging pathogens be made available early so that evaluations and validations can be undertaken by our customers as they recognize the coming needs of their labs,” Richard L. Eberly, president and CCO of Meridian Bioscience, said. "We are committed to growing our presence in the clinical market by expanding our menu of products to include ASRs and other early stage diagnostics. In the future, we expect to introduce additional ASRs as we expand this product line.”
Laboratories use ASR products to aid in the development and the validation of their own tests. There are currently no in vitro diagnostic products that will identify Clarithromycin-resistant strains available commercially in the United States. With the launch of Meridian’s ASR line an unmet need is fulfilled and laboratories can generate tests.